/l) and splenomegaly because of CML in November 1996. She received IFN-a from December 1996 to November 1998, when the drug was suspended for severe toxicity (hypothyroidism, depression of grade 3 according to WHO). From December 1998 to April 2003, the patient received chemotherapy (hydroxyurea and 6-mercaptopurine), remaining in the chronic phase of the disease. In April 2003, a BM analysis showed a progression of CML to accelerated phase and imatinib was started at a dose of 600 mg/day. The patient experienced two episodes of hematologic toxicity of grade 3 that required an interruption of the drug. During imatinib treatment, the patient reached a complete hematological remission without cytogenetic improvement, and in September 2004, a progression to myeloid blastic phase was diagnosed. At that time, the denaturing high-performance liquid chromatography (DHPLC) study did not reveal BCR-ABL mutations. mutations in the DHPLC study; liver enzymes increased and for this reason donor lymphocyte infusion (DLI) was not performed. Imatinib was then restarted at a dose of 400 mg/ day. In May 2007, RQ-PCR analysis showed an increased BCR-ABL-ABL ratio of 0.24% and the imatinib dose was increased to 600 mg/day, because the patient was at a highrisk of progression. Dose escalation did not improve molecular disease, as in August 2007, the ratio of BCR-ABL-ABL was 0.15%, although the liver function did worsen (toxicity grade 2-3). At that time, the DHPLC study did not reveal BCR-ABL mutations again and, because of severe intolerance to imatinib, dasatinib was started at a dose of 100 mg/day. Under this treatment, the patient experienced fever, bone pain and diarrhea of grade 3 according to WHO, which were attributed to dasatinib therapy, because they were not evident during high-dose imatinib. After 20 days of treatment, the blood lymphocyte count reached 3 Â 10 9 /l and then progressively dropped. After a period of interruption of 10 days, dasatinib was resumed at a dose of 50 mg once a day, but the patient experienced the same side effects again. The dose was then decreased to 20 mg/day without the recurrence of side effects, and in November 2007, after 3 months of treatment, RQ-PCR showed a ratio of 0.013%. No sign of CMV reactivation was evidenced during dasatinib treatment. The patient continued the same dasatinib dose and in May 2008, molecular analysis showed a ratio of 0.012%. In the same period, the liver enzymes decreased twice. Presently, the patient is in good clinical condition (at þ 15 months of treatment), with undetectable BCR-ABL-ABL ratio at RQ-PCR, confirmed at nested RT-PCR, under the same low dose of dasatinib.
Imatinib and dasatinib are both able to inhibit T-cell activation, but for imatinib the required concentrations are significantly higher than for dasatinib. 4 This latter drug appears, in fact, to be a more potent Lck inhibitor and acts as a potent immunomodulator at therapeutic levels.
Schade et al. 3 recently proved that dasatinib inhibits in vitro TCR signaling and expression of activation markers, cytokine production and proliferation. These authors showed that dasatinib is able to inhibit inflammation, leukocyte recruitment and host or allograft tissue destruction in vitro. GVHD can be considered as a threestep process in which the innate and adaptive immune systems interact: tissue damage to the recipient by the radiation/chemotherapy pre-transplant conditioning regimen; donor T-cell activation and clonal expansion; cellular and inflammatory factors. 5 More recently, Fei et al. 6 proved that dasatinib inhibited proliferation of CD8( þ )T cells in a dose-dependent manner, which was associated with a lower secretion of INF-g and granzyme B, as well as with an arrest of CD8( þ )T cells in the G(0)/G(1) phase of cell cycle.In a recent multicenter study, 19 Ph þ leukemia patients (9 CML CP, 2 CML AP, 2 CML BC and 6 Ph þ ALL), with marked lymphoproliferation in blood while on dasatinib, were described: clonality, immunophenotype and intracellular signaling were analyzed, and related clinical information was collected. Lymphocytosis with large granular lymphocyte expansion was observed after a median of 3 months from the start of therapy and all patients were exposed earlier to imatinib without similar changes. After dasatinib, a shift in the CD4/CD8 ratio, increased expression of activation Ags HLA-DR and CD57, decreased expression of homing Ag CD62L and relative numbers of regulatory T-cells were described. The authors suggested that through inhibition of immunoregulatory kinases, dasatinib may induce a reversible state of aberrant immune reactivity in a distinct subset of patients, which could result in anti-leukemia and anti-host responses driven by cytotoxic T/NK large granular lymphocyte cells. 7 Therefore, dasatinib might also alter the GVL effect and the GVHD sustained by CD8( þ )T cells after Allo-SCT. Moreover, dasatinib inhibits tyrosine phosphorylation of Src family kinases and downstream signal transducer and activator of transcription 5 (Stat5) signaling, with downregulation of expression of Stat5 target genes (Bcl-x, Mcl-1, cyclin D1). These effects, reported by Nam et al., 8 showed that blockade of Stat5 signaling by dasatinib is accompanied by inhibition of cell proliferation and induction of apoptosis.
In our case, dasatinib at a low dose was well-tolerated and the patient achieved a complete molecular response, while improving the liver dysfunction related to GVHD. A role for dasatinib as an anti-leukemic and immunosuppressant agent after SCT should therefore be investigated further.
